Amid global market volatility, TipRanks offers valuable tools to guide investors. One of the most powerful is the Smart Score, which assigns a ranking of one to ten to stocks and highlights their potential to outperform the broader market. Using this tool, we have identified three standout stocks: Keurig Dr Pepper (KDP), DraftKings (DKNG), and Jazz Pharmaceuticals (JAZZ). Each of these has earned a top Smart Score and a Strong Buy rating from Wall Street analysts.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Notably, the TipRanks Smart Score rates the stocks on a scale from 1 to 10, with 10 being the highest. The score is based on eight key market factors, including Wall Street analyst ratings, insider transactions, financial blogger opinions, and more. Additionally, the Top Smart Score Stocks list offers a comprehensive selection of stocks rated a perfect 10, along with advanced filtering options.
Let’s dive into the details.
Is KDP a Good Stock to Buy?
Based in the U.S., Keurig Dr Pepper is a beverage company with well-known brands like 7UP, Dr Pepper, Schweppes, and many more.
Year-to-date, KDP stock has gained nearly 5%. Looking ahead, Wall Street analysts remain highly bullish on its upside potential. Of the 15 analysts covering the stock, 12 rate it a Buy, while 3 have a Hold rating. The average KDP stock price target of $39.47 suggests a potential upside of over 17% from current levels.
Is DraftKings a Good Stock to Buy?
DraftKings is a gambling company, offering sportsbook and daily fantasy sports (DFS) services. So far in 2025, DKNG stock has soared over 15%.
Wall Street analysts are unanimously bullish on DKNG stock, with all 27 issuing Buy ratings. According to TipRanks’ consensus, the average DraftKings stock price target of $53.92 implies a potential upside of 26% from current levels.
Is JAZZ Stock a Good Buy?
Jazz Pharmaceuticals is a global biopharmaceutical company specializing in treatments for oncology and neuroscience-related conditions.
JAZZ stock holds a Strong Buy rating from Wall Street analysts. Out of 14 ratings, 13 are Buy and 1 is Hold. The average Jazz Pharmaceuticals stock price target of $176.64 suggests a potential upside of 58.3% from current levels. However, year-to-date, the stock is down 9.3%.
